Other languages Antengene Corporation Limited

Equities

6996

KYG039571008

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-05-14 am EDT			5-day change	1st Jan Change
0.97 ^HKD	0.00%		-9.35%	-51.50%

May. 02	Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop	MT
Apr. 29	Antengene Corporation Limited Announces That Dr. Kan Chen Will Not Offer Himself for Re-Election At the Annual General Meeting	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop	May. 02
Antengene Corporation Limited Announces That Dr. Kan Chen Will Not Offer Himself for Re-Election At the Annual General Meeting	Apr. 29
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study	Mar. 20
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance	Dec. 13
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	Dec. 10
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	Dec. 06
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	Nov. 16
Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031	23-09-21
Antengene Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China	23-08-10
Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	23-07-16
Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	23-05-31
Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers	23-05-23
Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031	23-05-17
Antengene Announces Five Presentations At the 2023 American Association for Cancer Research Meeting	23-04-17
Antengene Corporation Limited Announces Board Changes	23-04-14
Antengene Shrinks Loss in 2022 as Revenue Jumps Nearly Sixfold	23-03-28
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28
Antengene Corporation Limited Announces Approval for the Phase I Clinch Trial of ATG-022	23-03-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Antengene Corporation Limited

Equities

6996

KYG039571008

Other languages

Filters